ACTA Down, But what next?
The EU parliament has rejected the Anti-Countefeiting Trade Agreement (ACTA) but there are other similar moves to restrict free…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Category
Market
Moving with the market
Viveka Roychowdhury reports on the successful right sizing of strategies by both pharma MNCs and their Indian counterparts
Nurturing India’s small biotech
With India's DBT committing 30 per cent of its budget to PPPs, will these fund an ecosystem for small and medium sized companies…
Soaring High
Indian pharmaceutical companies in order mark its presence in the international markets, need to focus on regions having high…
Safer paths to greener pastures
With World Environment Day fast approaching, Usha Sharma analyses the pharma industry's measures to preserve the environment and…
Opportunities Galore for India’s Biotech Industry
India is an attractive destination for biotech enterpreneurs from across the globe and local companies are prising open this door…
M&A or MIA?
After witnessing watershed deals in the past few years, the M&A scenario in India seems to be MIA: Missing in Action. However,…
Beyond The Ban
The Government of India recently banned the use of serology-based test kits for diagnosis of tuberculosis. But this will translate…
CDSCO Draft Guidelines: Industry gives its verdict
Recently, the Central Drugs Standard Control Organisation (CDSCO) called for recommendations and suggestions on its draft…
DCGI to be competent national authority to certify API exports to EU
Draft guidelines for certification as per Falsified Medicines Directive, to be finalised by Jan 2013